{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:26:28Z","timestamp":1781177188367,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000999","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000999","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.ejim.2014.07.009","type":"journal-article","created":{"date-parts":[[2014,8,12]],"date-time":"2014-08-12T15:47:55Z","timestamp":1407858475000},"page":"751-756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Delphi consensus on the current clinical and therapeutic knowledge on Anderson\u2013Fabry disease"],"prefix":"10.1016","volume":"25","author":[{"given":"Daniela","family":"Concolino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Degennaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Parini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Antuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Bembi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Benso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Carraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Chimenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Colla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Cuonzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goffredo","family":"Del Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Diomedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Feliciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Feriozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ficcadenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Frustaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gnarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Maccarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelangelo","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Matucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Mignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Musumeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Nencini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Piga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Salviati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Spada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vultaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Zachara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Zedde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Giorgio","family":"Zoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2014.07.009_bb0005","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/GIM.0b013e3181f13b75","article-title":"Effects of enzyme replacement therapy in Fabry disease\u2014a comprehensive review of the medical literature","volume":"12","author":"Lidove","year":"2010","journal-title":"Genet Med"},{"key":"10.1016\/j.ejim.2014.07.009_bb0010","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry's disease","volume":"372","author":"Zarate","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2014.07.009_bb0015","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1517\/21678707.2013.776957","article-title":"Females and children with Anderson\u2013Fabry disease: diagnosis, monitoring, benefits of enzyme replacement therapy (ERT) and considerations on timing of starting ERT","volume":"1","author":"Parini","year":"2013","journal-title":"Expert Opin Orphan Drug"},{"key":"10.1016\/j.ejim.2014.07.009_bb0020","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.2174\/13816128113199990345","article-title":"Anderson\u2013Fabry disease in children","volume":"19","author":"Sestito","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ejim.2014.07.009_bb0025","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejim.2014.07.009_bb0030","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","article-title":"Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation","volume":"27","author":"Warnock","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejim.2014.07.009_bb0035","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF03261891","article-title":"Agalsidase alfa: a review of its use in the management of Fabry disease","volume":"26","author":"Keating","year":"2012","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejim.2014.07.009_bb0040","doi-asserted-by":"crossref","first-page":"916","DOI":"10.2174\/138920111795542705","article-title":"Treatment of Fabry disease: current and emerging strategies","volume":"12","author":"Rozenfeld","year":"2011","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.ejim.2014.07.009_bb0045","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/DDDT.S11985","article-title":"Update on role of agalsidase alfa in management of Fabry disease","volume":"5","author":"Ramaswami","year":"2011","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ejim.2014.07.009_bb0050","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/GIM.0b013e3181f13a4a","article-title":"Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry","volume":"12","author":"Watt","year":"2010","journal-title":"Genet Med"},{"key":"10.1016\/j.ejim.2014.07.009_bb0055","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/GIM.0b013e3181f9a056","article-title":"Agalsidase treatment for Fabry disease: uses and rivalries","volume":"12","author":"Schiffmann","year":"2010","journal-title":"Genet Med"},{"key":"10.1016\/j.ejim.2014.07.009_bb0060","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/1875397301004010050","article-title":"Fabry disease \u2014 current treatment and new drug development","volume":"4","author":"Motabar","year":"2010","journal-title":"Curr Chem Genomics"},{"key":"10.1016\/j.ejim.2014.07.009_bb0065","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/qjmed\/hcq117","article-title":"Fabry disease: a review of current management strategies","volume":"103","author":"Mehta","year":"2010","journal-title":"QJM"},{"key":"10.1016\/j.ejim.2014.07.009_bb0070","series-title":"The Delphi method, III: use of self ratings to improve group estimates","author":"Dalkey","year":"1969"},{"key":"10.1016\/j.ejim.2014.07.009_bb0075","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2014.07.009_bb0080","series-title":"Replagal (agalsidase alfa) 1mg\/ml concentrate for solution for infusion: summary of product characteristics","author":"Shire Human Genetic Therapies AB","year":"2013"},{"key":"10.1016\/j.ejim.2014.07.009_bb0085","series-title":"Fabrazyme (agalsidase beta) injection, powder, lyophilized for solution for intravenous use","author":"Genzyme Corporation","year":"2010"},{"key":"10.1016\/j.ejim.2014.07.009_bb0090","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2133.2007.08002.x","article-title":"Fabry disease and the skin: data from FOS, the Fabry outcome survey","volume":"157","author":"Orteu","year":"2007","journal-title":"Br J Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.ejim.2014.07.009_bb0095","first-page":"S94","article-title":"Angiokeratoma in Fabry disease: significant correlation between genotype and phenotype","volume":"35","author":"Orteu","year":"2012","journal-title":"J Inher Metab Dis"},{"key":"10.1016\/j.ejim.2014.07.009_bb0100","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/ejechocard\/jer109","article-title":"Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease","volume":"12","author":"Zamorano","year":"2011","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.ejim.2014.07.009_bb0105","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1067\/mhj.2000.105105","article-title":"New insights in cardiac structural changes in patients with Fabry's disease","volume":"139","author":"Linhart","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2014.07.009_bb0110","series-title":"Standard for infusion therapy: the RCN IV therapy forum","article-title":"Infusion equipment","author":"Royal College of Nursing","year":"2010"},{"key":"10.1016\/j.ejim.2014.07.009_bb0115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijcard.2011.03.023","article-title":"MR-based analysis of regional cardiac function in relation to cellular integrity in Fabry disease","volume":"160","author":"Koeppe","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2014.07.009_bb0120","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1651-2227.2008.00700.x","article-title":"Cardiac manifestations of Anderson\u2013Fabry disease in children and adolescents","volume":"97","author":"Kampmann","year":"2008","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.ejim.2014.07.009_bb0125","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/CIRCIMAGING.112.000070","article-title":"Identification and assessment of Anderson\u2013Fabry disease by cardiovascular magnetic resonance non-contrast myocardial T1 mapping","volume":"6","author":"Sado","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2014.07.009_bb0130","doi-asserted-by":"crossref","first-page":"W97","DOI":"10.2214\/AJR.08.1201","article-title":"Delayed-enhanced cardiac MRI for differentiation of Fabry's disease from symmetric hypertrophic cardiomyopathy","volume":"192","author":"De Cobelli","year":"2009","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ejim.2014.07.009_bb0135","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/eurheartj\/ehi143","article-title":"The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease","volume":"26","author":"Weidemann","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2014.07.009_bb0140","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11547-011-0710-9","article-title":"Role of cardiac MRI in evaluating patients with Anderson\u2013Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy","volume":"117","author":"Messalli","year":"2012","journal-title":"Radiol Med"},{"key":"10.1016\/j.ejim.2014.07.009_bb0145","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.amjcard.2005.11.087","article-title":"Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy","volume":"97","author":"Beer","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2014.07.009_bb0150","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcmg.2011.01.020","article-title":"Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment","volume":"4","author":"Niemann","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2014.07.009_bb0155","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI clinical practice guideline for diabetes and CKD: 2012 update","volume":"60","author":"KDOQI","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ejim.2014.07.009_bb0160","first-page":"437","article-title":"Cystatin C as a marker of early changes of renal function in Fabry nephropathy","volume":"20","author":"Feriozzi","year":"2007","journal-title":"J Nephrol"},{"key":"10.1016\/j.ejim.2014.07.009_bb0165","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ymgme.2011.06.021","article-title":"Cystatin C and NT-proBNP as prognostic biomarkers in Fabry disease","volume":"104","author":"Torralba-Cabeza","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ejim.2014.07.009_bb0170","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1093\/ndt\/gfq108","article-title":"The value of estimated GFR in comparison to measured GFR for the assessment of renal function in adult patients with Fabry disease","volume":"25","author":"Rombach","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejim.2014.07.009_bb0175","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/ndt\/gfp658","article-title":"Monitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based estimated glomerular filtration rate","volume":"25","author":"Tondel","year":"2010","journal-title":"Nephrol Dial Transplant"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095362051400209X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095362051400209X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T20:57:30Z","timestamp":1538341050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095362051400209X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S095362051400209X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2014.07.009","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delphi consensus on the current clinical and therapeutic knowledge on Anderson\u2013Fabry disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2014.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}